Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (CMO). In this role, Dr. Chu will ...
2023-06-30 12:31:22 ET Gainers: Cyteir Therapeutics ( CYT ) +39% . Renalytix ( RNLX ) +39% . Rackspace Technology ( RXT ) +29% . Friedman Industries ( FRD ) +23% . Gracell Biotechnologies ( GRCL ) +23% . CytomX Therapeutics (...
2023-06-30 10:06:37 ET Gainers: CymaBay Therapeutics ( CBAY ) +36% . Cyteir Therapeutics ( CYT ) +34% . Renalytix ( RNLX ) +32% . CytomX Therapeutics ( CTMX ) +14% . Alvotech ( ALVO ) +13% . Losers: Unicycive Therapeutics ...
- Financing is expected to extend cash runway into the 2 nd half of 2025 based on current operating plans, enabling the Company to reach multiple clinical milestones - - $30 million initial investment and up to $90 million in total potential funding - SOUTH SAN FRANCIS...
2023-06-12 04:39:44 ET Summary CytomX Therapeutics has an interesting platform. Its own proofing trials for the platform failed. However, big pharma is still very much interested, as 3 recent collaborative developments show. Two, three years ago, CytomX Therapeutics ...
SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Healthca...
2023-05-09 23:13:05 ET CytomX Therapeutics, Inc. (CTMX) Q1 2023 Results Conference Call May 09, 2023 5:00 PM ET Company Participants Chris Ogden - SVP, Finance & Accounting Sean McCarthy - CEO, Chairman Conference Call Participants Mitchell Kapoor - H...
2023-05-09 17:58:48 ET CytomX press release ( NASDAQ: CTMX ): Q1 GAAP EPS of -$0.05 beats by $0.06 . Revenue of $23.5M (+160.0% Y/Y) beats by $3.59M . For further details see: CytomX GAAP EPS of -$0.05 beats by $0.06, revenue of $23.5M beats by $3.59M
- Continued progress in Phase 1 dose escalation for CX-904 (EGFRxCD3) - - IND enabling activities on track for filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 - - Bristol Myers Squibb advances Anti-CTLA-4 non-fucosylated Probo...
2023-05-08 17:35:56 ET Major earnings expected after the bell on Tuesday include: Airbnb ( ABNB ) Occidental Petroleum Corporation ( OXY ) Twilio ( TWLO ) Virgin Galactic Holdings ( SPCE ) Upstart Holdings ( UPST ) For further details see: ...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...